Second eczema treatment pulled from PBS listing

Manufacturer calls for reform of Health Technology Assessment after dropping application to list an eczema treatment on the PBS  Pfizer withdraws application to list Cibinqo (abrocitinib) on the Pharmaceutical Benefits Scheme (PBS) over what it believes are unsustainable pricing and risk sharing arrangements.   The decision comes after the Pharmaceutical Benefits Advisory Committee (PBAC) recommended